Mayo Clinic: Uterine Cervical Neoplasms trials

The registry lists 12 Uterine Cervical Neoplasms studies with Mayo Clinic as lead sponsor. 8 are open to participants now and 1 have results posted.

Early Phase 1 1Phase 1 1Phase 2 2No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Community Based Intervention to Improve Cervical Cancer Screening Among Women in the Hispanic and East African Immigrant CommunityRecruitingNCT07890402Not applicable
• Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation TherapyRecruitingNCT07662824Not applicable
• The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasRecruitingNCT07285044Phase 2
• Offering HPV Self-Collection in Novel Healthcare Settings to Improve Uptake of Cervical Cancer ScreeningEnrolling by invitationNCT07186530Not applicable
• Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic PlatformRecruitingNCT06349642
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsRecruitingNCT05269381Phase 1/2
• Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical CancerRecruitingNCT05051722
• Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical CancerRecruitingNCT04567771Not applicable
• Pap Smear Collection With the Papette BrushCompletedNCT05034614Not applicableResults posted
• Barriers to Cervical Cancer ScreeningCompletedNCT06284447
• Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical CancerActive, not recruitingNCT04574635
• Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR MutationsCompletedNCT02646319Early Phase 1